Alpha 2.0
Login Register
» Authors » Lorne Albrecht

Lorne Albrecht

Explore the profile of Lorne Albrecht including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 67
Followers 0
Related Specialties
Dermatology
General Surgery
General Medicine
Top 10 Co-Authors
Kim A Papp
Melinda Gooderham
Melinda J Gooderham
Kim Papp
Yves Poulin
Lenka Rihakova
Chih-Ho Hong
Parbeer Grewal
Isabelle Delorme
Robert Gniadecki
Published In
J Cutan Med Surg
J Am Acad Dermatol
J Drugs Dermatol
Arch Dermatol Res
BMC Dermatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry
Papp K, Gooderham M, Lynde C, Brassard D, Al-Mohammedi F, Prajapati V, et al.
Arch Dermatol Res . 2024 Jun; 316(7):362. PMID: 38850346
Secukinumab is a fully human IgG1 antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin-17A. Secukinumab is an effective and well-tolerated treatment for plaque psoriasis. There is a...
2.
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial
Gold L, Adam D, Albrecht L, Alonso-Llamazares J, Ferris L, Gooderham M, et al.
J Am Acad Dermatol . 2024 Mar; 91(2):273-280. PMID: 38556093
Background: Efficacy and/or safety profiles limit topical psoriasis treatments. Objective: Evaluate long-term effects of once-daily roflumilast cream 0.3% in patients with psoriasis. Methods: In this open-label phase 2 trial, adult...
3.
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry
Gooderham M, Papp K, Lynde C, Delorme I, Beecker J, Albrecht L, et al.
Dermatol Ther (Heidelb) . 2022 Dec; 13(2):535-553. PMID: 36562944
Introduction: The association between physician-reported and patient-reported outcomes in patients with psoriasis is not adequately explored. Trends in PASI scores across body regions and the descriptive correspondence between physician-reported PASI...
4.
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials
Lebwohl M, Kircik L, Moore A, Gold L, Draelos Z, Gooderham M, et al.
JAMA . 2022 Sep; 328(11):1073-1084. PMID: 36125472
Importance: Once-daily roflumilast cream, 0.3%, a potent phosphodiesterase 4 inhibitor, demonstrated efficacy and was well tolerated in a phase 2b trial of patients with psoriasis. Objective: To evaluate the efficacy...
5.
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial
Gold L, Papp K, Pariser D, Green L, Bhatia N, Sofen H, et al.
J Am Acad Dermatol . 2021 Aug; 86(1):77-85. PMID: 34343599
Background: Patients with mild-to-moderate psoriasis may have substantial quality-of-life impairment. Objective: To evaluate apremilast 30 mg twice daily for mild-to-moderate psoriasis. Methods: Phase 3, double-blind, placebo-controlled study in adults with...
6.
Dermatologists' Perspectives on Defining Moderate Psoriasis: The Canadian Moderate Psoriasis Survey
Gooderham M, Papp K, Albrecht L, Grewal P, Gaudreau A
J Drugs Dermatol . 2021 Feb; 20(2):126-132. PMID: 33538558
Background: Psoriasis is commonly classified as either mild or moderate to severe, without specific parameters to differentiate moderate versus severe disease. This may lead to patients with moderate psoriasis being...
7.
Efficacy and safety of ingenol mebutate gel in field treatment of actinic keratosis on full face, balding scalp, or approximately 250 cm on the chest: A phase 3 randomized controlled trial
William Hanke C, Albrecht L, Skov T, Larsson T, Osterdal M, Spelman L
J Am Acad Dermatol . 2019 Aug; 82(3):642-650. PMID: 31374304
Background: Ingenol mebutate (IngMeb) 0.015% or 0.05% is approved for actinic keratosis (AK) areas of 25 cm or less; some patients require treatment of larger fields. Objective: To determine efficacy...
8.
Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America
Papp K, Gooderham M, Beecker J, Lynde C, Delorme I, Dei-Cas I, et al.
BMC Dermatol . 2019 Jun; 19(1):9. PMID: 31226985
Background: Treatment options for the management of moderate to severe plaque psoriasis include phototherapy, oral systemic agents, and biologic therapy. Secukinumab, a fully human monoclonal antibody that selectively targets IL-17A,...
9.
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section IV: Treatment Options for the Management of Atopic Dermatitis
Dhadwal G, Albrecht L, Gniadecki R, Poulin Y, Yeung J, Hong C, et al.
J Cutan Med Surg . 2018 Nov; 22(1_suppl):21S-29S. PMID: 30439301
The objectives of therapy for atopic dermatitis (AD) are to reduce skin inflammation and pruritus, restore skin barrier function, and improve quality of life (QoL). Treatments can be classified as...
10.
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Hong C, Gooderham M, Albrecht L, Bissonnette R, Dhadwal G, Gniadecki R, et al.
J Cutan Med Surg . 2018 Nov; 22(1_suppl):30S-35S. PMID: 30439300
This document is a concise, current, and practical guide for dermatologists and other health care providers managing adult patients with moderate-to-severe atopic dermatitis (AD). The recommendations made here are based...